Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | CPN1 | P15169 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4593370 | 0.97 | GNAI3 (0.47) | GNAI3GNAO1GNAI1CHRM2CHRM1 | |
| SCHEMBL15101461 | 0.91 | CHRM2 (0.41) | GNAI3GNAO1GNAI1CHRM2CHRM1 | |
| SCHEMBL3618718 | 0.91 | CHRM2 (0.41) | GNAI3GNAO1GNAI1CHRM2CHRM1 | |
| SCHEMBL2106403 | 0.91 | CHRM2 (0.41) | GNAI3GNAO1GNAI1CHRM2CHRM1 | |
| SCHEMBL4697949 | 0.85 | HPGD (0.38) | GNAI3GNAO1GNAI1CHRM2CHRM1 | |
| SCHEMBL8238 | 0.85 | — | — | |
| SCHEMBL798194 | 0.85 | — | — | |
| SCHEMBL794096 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL25253821 | 0.83 | GNAI3 (0.41) | GNAI3GNAO1GNAI1CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL16445991 | 0.83 | GNAI3 (0.41) | GNAI3GNAO1GNAI1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 691 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | claimed |
| CN-117642419-A | Compounds and compositions for targeted treatment of kidney disease | 上海盟科药业股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| EP-3743421-B1 | COMPOUNDS | UNIV OXFORD INNOVATION LTD (GB) | 2023-03-29 | — | — | EP | claimed |
| US-20210009576-A1 | COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-01-14 | — | — | US | claimed |
| EP-3743421-A1 | COMPOUNDS | Oxford University Innovation Limited (GB) | 2020-12-02 | — | — | EP | claimed |
| WO-2019145718-A1 | COMPOUNDS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-08-01 | — | — | WO | claimed |
| US-20150265733-A1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | Universität Bern (CH) | 2015-09-24 | — | — | US | claimed |
| CN-104080335-A | Certain chemical entities, compositions, and methods | QIAN XIANGPING | 2014-10-01 | — | — | CN | claimed |
| EP-2722051-A1 | Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus | Seattle Genetics, Inc. (US) | 2014-04-23 | — | — | EP | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | SEATTLE GENETICS, INC. (US) | 2009-01-15 | — | — | US | claimed |
| CN-1186332-C | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2005-01-26 | — | — | CN | claimed |
| CN-1337953-A | Novel thyroid receptor ligands and method II | KAROBIO AB (SE) | 2002-02-27 | — | — | CN | claimed |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-4074697-B1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | SAMJIN PHARM CO LTD (KR) | 2025-05-21 | — | — | EP | disclosed |
| CN-119613403-A | 4-Indolinyl substituted pyrido [3,2-d ] pyrimidine compounds and application thereof | 沈阳药科大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-88101286-A | 1-alkyl substituted benzimidazole derivatives, process for preparing same and pharmaceutical composition containing same | — | 1988-09-28 | — | — | CN | disclosed |
| CN-87100563-A | The anti-histamine compositions that contains N-heterocyclic radical-4-piperidinamines | — | 1987-08-19 | — | — | CN | disclosed |
| CN-85108556-A | The preparation method of novel benzoxazol base and benzothiazolyl amino derivative and application thereof | — | 1986-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009576-A1 | COMPOUNDS | KRAS, NRAS, HRAS | GNAI3 63/4885GNAO1 697/4885GNAI1 34/4885 |
| US-20150265733-A1 | BOMBESIN ANALOG PEPTIDE ANTAGONIST CONJUGATES | BRS3, VIP, GRPR | GNAI3 2870/4885GNAO1 2772/4885GNAI1 1877/4885 |
| US-20090018086-A1 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus | MMAB, DNPEP, MARCKS | GNAI3 3922/4885GNAO1 4539/4885GNAI1 4180/4885 |
| US-12590070-B2 | Adamantane derivatives as inhibitors of focal adhesion kinase | PTK2, CTTN, ADGRF1 | GNAI3 1452/4885GNAO1 630/4885GNAI1 1197/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | GNAI3 63/4885GNAO1 697/4885GNAI1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.